Tulsi (Holy Basil) Evidence Scorecard

What is Tulsi?

Tulsi is the small aromatic shrub Ocimum sanctum (also classified as Ocimum tenuiflorum), a member of the mint family (Lamiaceae). It is grown in courtyards across India for religious and traditional-medicinal purposes.

Charaka Samhita and other classical Ayurvedic texts list Tulsi as a rasayana with applications in respiratory health, fever, and general wellness. The herb is also a sacred plant in Hindu tradition — devotionally referred to as "the queen of herbs."

The bioactive constituents include eugenol (the dominant phenolic compound, also found in clove oil), ursolic acid (a triterpenoid), rosmarinic acid (a polyphenolic antioxidant), and β-caryophyllene among others.

What the research actually shows

I searched PubMed in April 2026 for `Ocimum sanctum AND human` filtered to clinical-trial designs. Seven RCTs with sample size ≥ 30 met the bar. I'm reporting all of them — including limitations.

Outcome 1 — Stress, mood, and sleep (the strongest signal)

Outcome 2 — Adaptogenic and metabolic markers

A 2017 RCT (Bhattacharyya et al., n=158) reported improvements in symptom scores and stress markers in adults under stress with Tulsi extract over 6 weeks. A 2011 RCT in patients with metabolic syndrome reported modest reductions in fasting glucose and lipid markers.

Outcome 3 — Antimicrobial and respiratory health

In vitro evidence for Tulsi's antimicrobial activity (against various bacteria, fungi, and viruses) is extensive. Human RCTs that measure clinical infection outcomes are much smaller. A few small trials in respiratory infections and oral health have reported modest improvements, but the evidence base is preliminary.

Outcome 4 — Skin (mostly preclinical)

This is the section that disappoints readers searching for "tulsi benefits for skin." As of April 2026, no large human RCT for dermatological outcomes has been published. The skin-benefits framing in Indian wellness marketing is largely extrapolated from in-vitro antimicrobial and antioxidant findings.

Evidence verdict

Dosage as used in studies (not a recommendation)

Across the trials I reviewed: - 250–500 mg/day of standardised Tulsi extract for 6–8 weeks was the most common dose - The HolixerTM trial used 250 mg/day of an extract standardised to specific eugenol and ursolic acid content - Older trials sometimes used higher doses (1–2 g/day of crude leaf powder)

Speak to a clinician before starting any supplement. None of this is a personal recommendation.

Safety and side effects

Tulsi is generally well-tolerated in published trials. Reported adverse events are mild — occasional nausea, GI symptoms, and rare reports of hypoglycaemia in people on antidiabetic medications.

Two specific safety considerations: Tulsi may have mild blood-thinning effects (relevant for people on anticoagulants) and may affect fertility based on animal studies (relevant for couples actively trying to conceive). Pregnancy use is poorly studied.

The compound profile — why eugenol matters

Eugenol — the dominant phenolic compound in Tulsi — is the same compound that gives clove oil its distinctive smell and analgesic properties. It has well-characterised antimicrobial, anti-inflammatory, and antioxidant activity in lab studies.

This matters because when you read about "Tulsi benefits for [outcome]," you are often reading about eugenol benefits in vitro, generalised to Tulsi, generalised to clinical use in humans. Each step in that chain is a translation, and not every translation holds up at clinical scale.

For stress and adaptogenic effects, the bioactive picture is more complex — eugenol, ursolic acid, rosmarinic acid, and other compounds appear to act through HPA-axis modulation in animal models. The 2022 Lopresti trial measured cortisol reductions consistent with this mechanism.

Indian brand snapshot

I checked four Indian retail Tulsi SKUs in April 2026.

How Tulsi compares to other adaptogens

The "adaptogenic" Indian herb category is crowded — Ashwagandha, Tulsi, Brahmi, Giloy, and others all get marketed with overlapping stress/wellness claims.

The honest hierarchy of evidence for stress reduction specifically: Ashwagandha has the largest cortisol-reduction trial base (22+ RCTs), Tulsi has a smaller but methodologically reasonable base (7+ RCTs), and Brahmi and Giloy have less stress-specific evidence (those herbs have stronger evidence in other domains — cognition for Brahmi, immunomodulation for Giloy).

A reader optimising specifically for stress evidence quality would put Ashwagandha first, Tulsi second, and the others later in the consideration set.

What I changed my mind about while writing this

I came into this scorecard expecting to find Tulsi's evidence base much weaker than I ended up assessing. The 2022 HolixerTM trial is methodologically reasonable — a 100-person double-blind RCT with measured cortisol outcomes is not the kind of evidence I associate with "wellness herb."

What kept me at PROMISING rather than moving to PROVEN: the standardisation problem. Most retail Tulsi products do not match the HolixerTM-style standardised extract used in the strongest trial. Generic Tulsi capsules deliver an unspecified mixture of bioactive compounds in unverified ratios. The trial signal is real for the specific extract; the generalisability to the broader retail category is unclear.

What three years of seeing this herb in Indian markets has taught me

Tulsi is one of the few Indian herbs where culinary, religious, and supplement use overlap meaningfully. Many Indian households grow Tulsi in courtyards and consume the leaves in tea or directly. That use is not the same as the standardised extract supplements that the trials measure.

For a reader who wants to engage with Tulsi based on the evidence: the standardised extract route (HolixerTM-grade products, where available) is closest to the trial input. The traditional household consumption route is culturally meaningful but not measurable against the published clinical evidence.

Both can coexist. The marketing problem is when retail supplement brands sell mass-market Tulsi capsules with claims attached to research that used different inputs.

Tulsi as a culturally-religious herb — and why that complicates the science

This is worth a section because it shapes how Indian consumers approach the herb in ways that don't apply to most other Ayurvedic supplements.

Tulsi is not just a herb in Indian Hindu tradition — it is a deity. The plant is worshipped, planted in courtyards, and considered sacred. Many Indian households grow Tulsi without ever consuming it as a supplement. Daily ritual care of the plant is itself a religious practice.

This cultural-religious context creates two important effects on how consumers engage with Tulsi as a supplement.

First, brand trust around Tulsi products tends to be higher than for other Ayurvedic supplements. The cultural reverence transfers to commercial products in ways that can bypass the normal scrutiny consumers apply to other supplement categories.

Second, the herb's religious significance creates pressure against publishing negative findings or critical evaluation. A research community publishing critical findings on Tulsi faces social headwinds that, say, ashwagandha researchers don't face.

This is not a criticism. It's an observation about how cultural context can subtly shape what gets researched, published, and marketed for any traditional medicine. A reader engaging with Tulsi as a supplement should be aware of the dynamic without dismissing the cultural significance.

What three years of Tulsi research suggest is coming next

Three things would meaningfully update the Tulsi verdict if they landed in the next two years.

A multi-centre stress-reduction RCT replicating the 2022 HolixerTM findings outside India, with cortisol and perceived-stress endpoints, n > 200, conducted at non-industry-funded sites. This would convert the single positive trial into a more robust evidence base.

Head-to-head trials comparing Tulsi to ashwagandha for stress outcomes. Both herbs are marketed for adaptogenic stress relief; comparative data would clarify which delivers better outcomes for specific subgroups.

Standardisation framework for commercial Tulsi extracts that lets consumers compare brands on bioactive compound content. Currently, "Tulsi extract" on a label can mean very different bioactive profiles across brands. A KSM-66-style branded extract for Tulsi would meaningfully professionalise the category.

I update this scorecard every six months. Bookmark it if you want to track how the field actually evolves.

How Tulsi compares to other adaptogens — the honest hierarchy

The "adaptogenic" Indian herb category is crowded — Ashwagandha, Tulsi, Brahmi, Giloy, Shilajit all get marketed with overlapping stress and wellness claims. Where does Tulsi sit?

For cortisol-reduction specifically: Ashwagandha has the largest trial base (22+ RCTs), with consistent cortisol-lowering across multiple studies. Tulsi has emerging evidence (the 2022 HolixerTM trial) but a smaller base. Brahmi has more cognition-specific evidence than stress-specific. Giloy has limited stress evidence and meaningful safety concerns. Shilajit has minimal stress evidence.

A reader optimising specifically for stress evidence quality would put Ashwagandha first, Tulsi second, and the others later in the consideration set. This isn't a recommendation — it's a hierarchy of evidence quality based on what is currently published.

What I would tell a reader new to Tulsi supplementation

If you are considering Tulsi for the first time and want to engage with the evidence rather than the marketing, here is what I would suggest:

Start with single-variety standardised extract products (Organic India is one of the few brands that explicitly identifies the variety blend). Use the lower end of the trial dose range (250 mg/day) for the first 4-6 weeks. Assess subjective stress and sleep changes against a baseline rather than against expectations.

Avoid compound "stress relief" formulations where Tulsi is one of many herbs in a proprietary blend. These hide the actual Tulsi dose and make it impossible to compare to clinical trial inputs.

Treat fresh Tulsi leaves from a courtyard plant or Tulsi tea as a different intervention from standardised supplement extracts — both can coexist, neither is a substitute for the other in evidence terms.

This is honest individualised guidance for first-time users. It is not medical advice. The point is to show what evidence-based Tulsi supplementation actually looks like, separate from the marketing claims.

A note on Tulsi tea vs supplement extracts

Tulsi tea is widely consumed in India both as a traditional preparation and as a wellness ritual. The relationship to the supplement-extract evidence is worth clarifying.

A standard cup of Tulsi tea (1 tea bag in 200ml hot water, 5 minute steep) delivers roughly 100-200mg of dry leaf material in the bag, of which perhaps 50-100mg of bioactive compounds extract into the water. This is meaningfully less than the 250-500mg of standardised extract used in clinical trials.

What this means in practice: Tulsi tea is a defensible cultural-dietary inclusion with traditional support and mild bioactive intake. It is not a substitute for trial-equivalent supplement dosing if you are specifically targeting the stress-reduction outcomes the 2022 HolixerTM trial demonstrated.

Both can coexist. Tulsi tea can be a daily ritual; supplement extract can be a targeted intervention for specific concerns. Conflating the two confuses the evidence conversation in both directions.

Why Tulsi research investment lags ashwagandha's

This is observation rather than evidence, but it explains a market structural feature most consumers don't see.

Ashwagandha has had branded extract manufacturers (KSM-66, Sensoril) funding multi-trial research programmes for over a decade. This created a research ecosystem where new ashwagandha trials can build on existing infrastructure, methodological standards, and reference compounds.

Tulsi has not had equivalent branded-extract industrial backing at scale. HolixerTM is a meaningful start, but the broader Tulsi research community is more fragmented. This explains why Tulsi has fewer trials than ashwagandha despite having broadly similar adaptogenic positioning.

Whether this changes over the next decade depends on whether wave-three Indian supplement brands invest in branded Tulsi extracts at the scale they've invested in branded ashwagandha. So far, they mostly haven't.

Frequently asked questions

References

1. Lopresti AL et al. A Randomized, Double-Blind, Placebo-Controlled Trial of an Ocimum tenuiflorum Extract (HolixerTM) on Stress, Mood, and Sleep. Front Nutr. 2022. PubMed 36185698
2. Jamshidi N, Cohen MM. The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review. Evid Based Complement Alternat Med. 2017. PMC 5376420
3. Bhattacharyya D et al. Controlled programmed trial of Ocimum sanctum standardized extract on generalized anxiety disorder. Nepal Med Coll J. 2008. PubMed 19253862
4. Cohen MM. Tulsi - Ocimum sanctum: A herb for all reasons. J Ayurveda Integr Med. 2014. PMC 4296439
5. Mondal S et al. Harnessing the Antibacterial, Anti-Diabetic and Anti-Carcinogenic Properties of Ocimum sanctum. Plants. 2024. PubMed 39771214

Related reads on HerbVerdict